Orthocell
- Short interest
- 0.03%
- −0.23 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 69.3K
- Shares on issue
- 272.394M
Orthocell (OCC) Short Interest
Orthocell (ASX:OCC) had 0.03% of shares reported as short positions as of 8 Oct 2026, representing 69,327 shares. Orthocell operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Orthocell
Orthocell is a leader in the regenerative medicine sector, focusing on innovative treatments for chronic degenerative diseases and injuries. The company specializes in developing collagen medical devices and cell therapies that leverage the body's natural repair mechanisms. Orthocell's products are designed to enhance surgical repair and promote tissue regeneration, positioning it as a pioneer in the biotechnology and life sciences industry.
Company profile →Orthocell (ASX:OCC) has 0.03% of its shares on issue reported as short positions as of 8 Oct 2026, or about 69,327 shares. Over the past 30 days that figure has fallen 0.23 percentage points, and over 90 days it has fallen 0.36 percentage points. Its highest recorded short interest was 0.94% in December 2025. OCC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads OCC today
- Zanger BreakoutWatchScore 38rank 277 of 1931
- CAN SLIMWatchScore 14rank 976 of 1541
- Minervini Trend TemplateWatchScore 6rank 1702 of 1736
- Crowded-Short BreakoutWatchScore 6rank 1461 of 1479
- Quality compoundersWatchScore 31rank 410 of 1677
Prices to 13 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
OCC fundamentals
In the year to 30 Jun 2026, Orthocell (ASX:OCC) recorded revenue of A$11.4M and a net loss after tax of A$13.9M. A year earlier it recorded revenue of A$7.6M and a net loss after tax of A$8.6M. Year-on-year growth: revenue +51.1% (FY). Net margin −122.0%, return on equity −56.8% (FY). Figures are in AUD, the company's reporting currency; source: Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest OCC news
All news- Orthocell nerve repair product Remplir shows promise in prostate cancer surgery
stockhead · 13 Oct 2026
- Remplir Shows Excellent Early Prostatectomy Results
asx · 12 Oct 2026
- Letter to Shareholders, Notice of AGM & Proxy Form
asx · 1 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss OCC
Start a research thread or post the first pulse update